

Phase II comparison of accelerated twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with etoposide and cisplatin

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/10/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr C Faivre-Finn

Contact details

Clinical Oncology
Christie Hospital NHS Trust
Wilmslow Road
Withington
Manchester
United Kingdom
M20 4BX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0063115998

Study information

Scientific Title

Study objectives

This randomised phase II trial is aiming to assess the acute toxicity of twice-daily and once-daily concurrent chemo-radiotherapy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cancer: Limited small-cell lung cancer

Interventions

Arm A: new total dose of 66 Gy given over 45 days once-daily concurrently with chemotherapy

Arm B: total 45 Gy given over 19 days twice-daily concurrently with chemotherapy

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

etoposide and cisplatin

Primary outcome measure

Acute toxicity (particularly grade III/IV oesophagitis).

Secondary outcome measures

1. Overall survival
2. Response rates

Overall study start date

01/09/2002

Completion date

31/12/2008

Eligibility

Key inclusion criteria

Patients who are ≤ 75 years of age with histologically proven small-cell lung cancer and fully meet the criteria will be approached for consent. 81 Patients in total will be recruited for the trial and 27 will be recruited to the standard arm and 54 to the experimental arm. 25 patients per year.

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

81

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/09/2002

Date of final enrolment

31/12/2008

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Clinical Oncology
Manchester
United Kingdom
M20 4BX

Sponsor information

Organisation
Department of Health (UK)

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
<http://www.doh.gov.uk>

Funder(s)

Funder type
Government

Funder Name
Christie Hospital NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article				Yes	No